The challenge of pain in the pharmacological management of Parkinson’s disease

References

• Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124:901–905.
   PubMed Web of Science ®Google Scholar
• Defazio G, Gigante A, Mancino P, et al. The epidemiology of pain in Parkinson’s disease. J Neural Transm (Vienna). 2013;120:583–586.
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Molloy S, et al. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord. 2010;25:1646–1651.
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25:2493–2500.
   PubMed Web of Science ®Google Scholar
• Nègre-Pagès L, Regragui W, Bouhassira D, et al. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMIP survey. Mov Disord. 2008;23:1361–1369.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Dellapina E, et al. Emerging analgesic drugs for Parkinson’s disease. Expert Opin Emerging Drugs. 2012;17:157–171.
   PubMed Web of Science ®Google Scholar
• Buhmann C, Wrobel N, Grashorn W, et al. Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. J Neurol. 2017;264:758–769.
   PubMed Web of Science ®Google Scholar
• Csoti I, Herbst H, Urban P, et al. Polypharmacy in Parkinson’s disease – risks and benefits without evidence. J Neural Transm. 2019. DOI:10.1007/s00702-019-02026-8
   PubMed Web of Science ®Google Scholar
• Farnikova K, Krobot A, Karnovsky P. Musculoskeletal problems as an initial manifestation of Parkinson’s disease: a retrospective study. J Neurol Sci. 2012;319:102–104.
   PubMed Web of Science ®Google Scholar
• Beiske AG, Loge JH, Rønningen A, et al. Pain in Parkinson’s disease: prevalence and characteristics. Pain. 2009;141:173–177.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study. A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–1649.
   PubMed Web of Science ®Google Scholar
• Broen MP, Braaksma MM, Patiin J, et al. Prevalence of pain in Parkinson’s disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012;27:480–484.
   PubMed Web of Science ®Google Scholar
• Hanagasi HA, Akat S, Gurvit H, et al. Pain is common in Parkinson’s disease. Clin Neurol Neurosurg. 2011;113:11–13.
   PubMed Web of Science ®Google Scholar
• Lee MA, Walker RW, Hildreth TJ, et al. A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manage. 2006;32:462–469.
   PubMed Web of Science ®Google Scholar
• Qureshi AR, Rana AQ, Malik SH, et al. Comprehensive examination of therapies for pain in Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2018;51:190–206.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Rizos A, Trenkwalder C, et al. King’s Parkinson’s disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30:1623–1631.
   PubMed Web of Science ®Google Scholar
• Blanchet PJ, Brefel-Courbon C. Chronic pain and pain processing in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2018;87(Pt B):200–206.
   PubMedGoogle Scholar
• Wasner G, Deuschl G. Pains in Parkinson disease – many syndromes under one umbrella. Nat Rev Neurol. 2012;8:284–294.
   PubMed Web of Science ®Google Scholar
• Ozturk EA, Kocer BG. Predictive risk factors for chronic low back pain in Parkinson’s disease. Clin Neurol Neurosurg. 2018;164:190–195.
   PubMed Web of Science ®Google Scholar
• Broetz D, Eichner M, Gasser T, et al. Radicular and nonradicular back pain in Parkinson’s disease: a controlled study. Mov Disord. 2007;22:853–856.
   PubMed Web of Science ®Google Scholar
• Moreno CB, Hernández-Beltrán N, Munévar D, et al. Central neuropathic pain in Parkinson’s disease. Neurología. 2012;27:500–503.
   PubMed Web of Science ®Google Scholar
• Zambito-Marsala S, Erro R, Bacchin R, et al. Abnormal nociceptive processing occurs centrally and not peripherally in pain-free Parkinson disease patients: A study with laser-evoked potentials. Parkinsonism Relat Disord. 2017;34:43–48.
   PubMed Web of Science ®Google Scholar
• Ehrt U, Larsen JP, Aarsland D. Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry. 2009;17:269–275.
   PubMed Web of Science ®Google Scholar
• Rana AQ, Qureshi ARM, Rahman N, et al. Disability from pain directly correlated with depression in Parkinson’s disease. Clin Neurol Neurosurg. 2017;160:1–4.
   PubMed Web of Science ®Google Scholar
• Greenbaum L, Tegeder I, Barhum Y, et al. Contribution of genetic variants to pain susceptibility in Parkinson disease. Eur J Pain. 2012;16:1243–1250.
   PubMed Web of Science ®Google Scholar
• Li W, Chen Y, Yin B, et al. Pain in Parkinson’s disease associated with COMT gene polymorphisms. Behav Neurol. 2014;2014:304203.
   PubMed Web of Science ®Google Scholar
• Zambito Marsala S, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson’s disease. J Neurol. 2011;258:627–633.
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Del Vesco C, Fincati E, et al. Pain and motor complications in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77:822–825.
   PubMed Web of Science ®Google Scholar
• Valkovic P, Minar M, Singliarova H, et al. Pain in Parkinson’s disease: a cross-sectional study of its prevalence, types, and relationship to depression and quality of life. PLoS One. 2015;10:e0136541.
   PubMed Web of Science ®Google Scholar
• Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology. 2013;80:800–809.
   PubMed Web of Science ®Google Scholar
• Sung S, Vijiaratnam N, Chan DWC, et al. Pain sensitivity in Parkinson’s disease: systematic review and meta-analysis. Parkinsonism Relat Disord. 2018;48:17–27.
   PubMed Web of Science ®Google Scholar
• Mylius V, Pee S, Pape H, et al. Experimental pain sensitivity in multiple system atrophy and Parkinson’s disease at an early stage. Eur J Pain. 2016;20:1223–1228.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.
   PubMed Web of Science ®Google Scholar
• Grashorn W, Schunke O, Buhmann C, et al. Influence of dopaminergic medication on conditioned pain modulation in Parkinson’s disease patients. PLoS One. 2015;10:e0135287.
   PubMed Web of Science ®Google Scholar
• Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2005;20:1557–1563.
   PubMed Web of Science ®Google Scholar
• Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78:1140–1142.
   PubMed Web of Science ®Google Scholar
• Quinn NP, Koller WC, Lang AE, et al. Painful Parkinson’s disease. Lancet. 1986;1(8494):1366–1369.
   PubMed Web of Science ®Google Scholar
• Reichling DB, Levine JD. Pain and death: neurodegenerative disease mechanisms in the nociceptor. Ann Neurol. 2011;69:13–21.
   PubMed Web of Science ®Google Scholar
• Tseng MT, Lin CH. Pain in early-stage Parkinson’s disease: implications from clinical features to pathophysiology mechanisms. J Formos Med Assoc. 2017;116:571–581.
   PubMed Web of Science ®Google Scholar
• Conte A, Khan N, Defazio G, et al. Pathophysiology of somatosensory abnormalities in Parkinson disease. Nat Rev Neurol. 2013;9:687–697.
   PubMed Web of Science ®Google Scholar
• Mouraux A, Diukova A, Lee MC, et al. A multisensory investigation of the functional significance of the “pain matrix”. Neuroimage. 2011;54:2237–2249.
   PubMed Web of Science ®Google Scholar
• Fil A, Cano-de-la-Cuerda R, Muñoz-Hellín E, et al. Pain in Parkinson disease: a review of the literature. Parkinsonism Relat Disord. 2013;19:285–294.
   PubMed Web of Science ®Google Scholar
• Ford B. Pain in Parkinson’s disease. Mov Disord. 2010;25(Suppl 1):S98–103.
   PubMed Web of Science ®Google Scholar
• Skogar O, Lokk J. Pain management in patients with Parkinson’s disease: challenges and solutions. J Multidiscip Healthc. 2016;9:469–479.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61:1563–1568.
   PubMed Web of Science ®Google Scholar
• Lin CH, Wu RM, Chang HY, et al. Preceding pain symptoms and Parkinson’s disease: a nationwide population-based cohort study. Eur J Neurol. 2013;20:1398–1404.
   PubMed Web of Science ®Google Scholar
• Ren L, Yi J, Yang J, et al. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: a dose–response meta-analysis. Medicine (Baltimore). 2018;97:e12172.
   PubMed Web of Science ®Google Scholar
• Madeo G, Schirinzi T, Natoli S, et al. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain. J Neurol. 2015;262(9):2164–2170.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Chaudhuri KR, Martinez-Martin P, et al. Prolonged release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14:1161–1170.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Preziosi TJ, Robinson RG. Sleep disorders, pain, and depression in Parkinson’s disease. Eur Neurol. 1991;313:52–55.
   Google Scholar
• Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007;30:201–205.
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113–e88.
   PubMed Web of Science ®Google Scholar
• Quintero JE, Dooley DJ, Pomerleau F, et al. Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ α2δ-1 subunit. J Pharmacol Exp Ther. 2011;338:240–245.
   PubMed Web of Science ®Google Scholar
• Watson CJ. Insular balance of glutamatergic and GABAergic signaling modulates pain processing. Pain. 2016;157:2194–2207.
   PubMed Web of Science ®Google Scholar
• Parsons B, Argoff CE, Clair A, et al. Improvement in pain severity category in clinical trials of pregabalin. J Pain Res. 2016;9:779–785.
   PubMed Web of Science ®Google Scholar
• Olson WL, Gruenthal M, Mueller ME, et al. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med. 1997;102:60–66.
   PubMed Web of Science ®Google Scholar
• Van Blercom N, Lasa A, Verger K, et al. Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease. Clin Neuropharmacol. 2004;27:124–128.
   PubMed Web of Science ®Google Scholar
• Lotan I, Treves TA, Roditi Y, et al. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol. 2014;37:41–44.
   PubMed Web of Science ®Google Scholar
• Shohet A, Khlebtovsky A, Roizen N, et al. Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson’s disease. Eur J Pain. 2017;21:486–493.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Barone P, Bonizzoni E, et al. Effects of safinamide on pain in fluctuating Parkinson’s disease patients: A post-hoc analysis. J Parkinsons Dis. 2017;7:95–101.
   PubMedGoogle Scholar
• Cattaneo C, Kulisevsky J, Tubazio V, et al. Long-term efficacy of safinamide on Parkinson’s disease chronic pain. Adv Ther. 2018;35:515–522.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90–99.
   PubMed Web of Science ®Google Scholar
• Kassubek J, Chaudhuri KR, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014;14:42.
   PubMed Web of Science ®Google Scholar
• Timmermann L, Oehlwein C, Ransmayr G, et al. Patients’ perception of Parkinson’s disease-associated pain following initiation of rotigotine: a multicenter non-interventional study. Postgrad Med. 2017;129(1):46–54.
   PubMed Web of Science ®Google Scholar
• Antonini A, Yegin A, Preda C, et al. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21:231–235.
   PubMed Web of Science ®Google Scholar
• Zibetti M, Merola A, Artusi CA, et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol. 2014;21:312–318.
   PubMed Web of Science ®Google Scholar
• Verhagen Metman L, Del Dotto P, van Den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50:1323–1326.
   PubMed Web of Science ®Google Scholar
• Rieu I, Degos B, Castelnovo G, et al. Incobotulinum toxin A in Parkinson’s disease with foot dystonia: a double blind randomized trial. Parkinsonism Relat Disord. 2018;46:9–15.
   PubMed Web of Science ®Google Scholar
• Bruno V, Freitas ME, Mancini D, et al. Botulinum toxin type A for pain in advanced Parkinson’s disease. Can J Neurol Sci. 2018;45:23–29.
   PubMed Web of Science ®Google Scholar
• Bleasdale-Barr KM, Mathias CJ. Neck and other muscle pains in autonomic failure: their association with orthostatic hypotension. J R Soc Med. 1998;91:355–359.
   PubMed Web of Science ®Google Scholar
• Jost WH. Autonomic dysfunction in Parkinson’s disease: cardiovascular symptoms, thermoregulation, and urogenital Symptoms. Int Rev Neurobiol. 2017;134:771–785.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59:421–424.
   PubMed Web of Science ®Google Scholar
• Rana AQ, Siddiqui I, Mosabbir A, et al. Association of pain, Parkinson’s disease, and restless legs syndrome. J Neurol Sci. 2013;327:32–34.
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria–history, rationale, description, and significance. Sleep Med. 2014;15:860–873.
   PubMed Web of Science ®Google Scholar
• Winkelmann J, Allen RP, Högl B, et al. Treatment of restless legs syndrome: evidence-based review and implications for clinical practice. Mov Disord. 2018;33:1077–1091.
   PubMed Web of Science ®Google Scholar
• Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord. 2001;16:1176–1177.
   PubMed Web of Science ®Google Scholar